Evidence map›Paper›PMID 35277779›Full record

ArticleBiotechnology letters2022

Antigenic and conserved peptides from diverse Helicobacter pylori antigens.

Cecília R C Calado

Abstract read
In one paragraph

Article in Biotechnology letters, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Correlation betweenMicrobiology spectrum · 2025
    Article
  3. Article
  4. Article
  5. Developing a potent vaccine againstExpert reviews in molecular medicine · 2024
    Review
  6. Article
  7. How Long Will It Take to Launch an EffectiveInfection and drug resistance · 2023
    Review
  8. Article
  9. Journal of clinical medicine · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Cecília R C CaladoCIMOSM - Centro de Investigação em Modelação e Otimização de Sistemas Multifuncionais, ISEL - Instituto Superior de Engenharia de Lisboa, Instituto Politécnico de Lisboa, R. Conselheiro Emídio Navarro 1, 1959-007, Lisboa, Portugal. cecilia.calado@isel.pt.ORCID http://orcid.org/0000-0002-5264-9755

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since the revolutionary finding of Helicobacter pylori as a common bacterial infection, that a high research effort for its eradication has been conducted. Epitope based-vaccine presents advantages over protein-based, as they can be designed to contain epitopes from diverse proteins, therefore, more easily representing the immune-variability of the bacterial population, while minimizing the toxicity associated to some whole proteins. In the present work, an iterative method, to design antigenic and conserved B-epitopes from diverse virulent factors of H. pylori, was established. The method considered the trade-off between epitopes antigenicity and conservation among the bacterial population. For the method validation, five virulent factors from H. pylori were selected. From each virulent factor, two epitopes were predicted, each with twelve residues of aminoacids. The corresponding ten peptides were synthesised and evaluated by enzyme-linked immunosorbent assay using polyclonal antibodies raised against a specific H. pylori strain. All ten peptides were recognised by the antibodies and were consequently antigenic and conserved. This result could strongly contribute to the design of a multivalent epitope-based vaccine, representing the immunogenetic variability within the bacterial population, leading to a sustained and effective immunogenic protection.

Indexed as

Helicobacter InfectionsHelicobacter pyloriAnimalsAntibodies, BacterialAntigens, BacterialBacterial VaccinesEpitopesMiceMice, Inbred BALB CPeptidesUreaseAntibodies, BacterialAntigens, BacterialBacterial VaccinesEpitopesPeptidesUreaseEpitopesHelicobacter pyloriMulti-antigensPeptideVaccine

Identifiers

PMID35277779
PMCPMC8916697

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.